Proteomics

Dataset Information

0

Proteomics of prostate cancer patient derived xenografts

ABSTRACT: A set of 17 prostate cancer patient-derived xenografts (PDX, Lin et al 2014, Cancer research) was analyzed by mass spectrometry-based proteomics to characterize the effects of castration in vivo, and the proteome differences between NEPC and prostate adenocarcinomas.

INSTRUMENT(S): Q Exactive

ORGANISM(S): Homo Sapiens (human)

TISSUE(S): Prostate Cancer Cell

DISEASE(S): Prostate Adenocarcinoma

SUBMITTER: Diego Iglesias-Gato  

LAB HEAD: Diego Iglesias-Gato

PROVIDER: PXD009636 | Pride | 2019-09-11

REPOSITORIES: Pride

Json Xml

Dataset's files

Source:
Action DRS
20140806_QE3_UPLC10_TSB_SA_COLLAB_1A.raw Raw
20140806_QE3_UPLC10_TSB_SA_COLLAB_1B.raw Raw
20140806_QE3_UPLC10_TSB_SA_COLLAB_1C.raw Raw
20140806_QE3_UPLC10_TSB_SA_COLLAB_1D.raw Raw
20140806_QE3_UPLC10_TSB_SA_COLLAB_1E.raw Raw
Items per page:
1 - 5 of 88
altmetric image

Publications

Proteogenomic Characterization of Patient-Derived Xenografts Highlights the Role of REST in Neuroendocrine Differentiation of Castration-Resistant Prostate Cancer.

Flores-Morales Amilcar A   Bergmann Tobias B TB   Lavallee Charlotte C   Batth Tanveer S TS   Lin Dong D   Lerdrup Mads M   Friis Stine S   Bartels Anette A   Kristensen Gitte G   Krzyzanowska Agnieszka A   Xue Hui H   Fazli Ladan L   Hansen Klaus H KH   Røder Martin A MA   Brasso Klaus K   Moreira José M JM   Bjartell Anders A   Wang Yuzhuo Y   Olsen Jesper V JV   Collins Colin C CC   Iglesias-Gato Diego D  

Clinical cancer research : an official journal of the American Association for Cancer Research 20181001 2

<h4>Purpose</h4>An increasing number of castration-resistant prostate cancer (CRPC) tumors exhibit neuroendocrine (NE) features. NE prostate cancer (NEPC) has poor prognosis, and its development is poorly understood.<b>Experimental Design:</b> We applied mass spectrometry-based proteomics to a unique set of 17 prostate cancer patient-derived xenografts (PDX) to characterize the effects of castration <i>in vivo</i>, and the proteome differences between NEPC and prostate adenocarcinomas. Genome-wi  ...[more]

PMID: 30274982

Publication: 1/2

Similar Datasets

Proteomics Prostate cancer progression: From non-malignant to bone metastasisProstate cancer progression: From non-malignant to bone metastasis
2018-08-21 | PXD009868 | Pride
Proteomics The proteome of localized prostate cancer, part 1
2016-06-01 | PXD003430 | Pride
Proteomics The proteome of localized prostate cancer, part 3
2016-06-01 | PXD003515 | Pride
Proteomics The proteome of localized prostate cancer, part 4
2016-06-01 | PXD004132 | Pride
Proteomics The proteome of localized prostate cancer, part 5
2016-06-01 | PXD003615 | Pride
Proteomics The proteome of localized prostate cancer, part 7
2016-06-01 | PXD004159 | Pride
Proteomics The proteome of localized prostate cancer, part 6
2016-06-01 | PXD003636 | Pride
Proteomics The proteome of localized prostate cancer, part 2
2016-06-01 | PXD003452 | Pride
Proteomics RET Kinase Inhibition in Neuroendocrine Prostate Cancer, part 2
2020-05-29 | PXD012971 | Pride
Proteomics RET Kinase Inhibition in Neuroendocrine Prostate Cancer, part 1
2020-05-29 | PXD012970 | Pride